ADHD Foundation working with two med-tech companies to launch and pilot breakthrough technologies in ADHD intervention and diagnosis
Revolutionary new technologies to help with the management of ADHD (Attention Deficit Hyperactivity Disorder) will be launched and piloted by leading ADHD charity, ADHD Foundation, for the first time in the UK.
QbCheck, the world’s first online ADHD test that is both FDA cleared and CE-marked is being launched at the ADHD Foundation conference in Liverpool this week. QbCheck is used to inform referral decisions by teachers and by qualified healthcare professionals to aid diagnosis and track treatment effectiveness. The average delay to ADHD diagnosis in Europe is four years, during which time education and mental health can suffer. With QbCheck, teachers can ensure that pupils reach the clinic sooner and benefit from treatment. They can also use the results to determine the best way to support the pupils in class.
ADHD currently affects one in 20 children and a third of those children are still symptomatic as adults. Those currently seeking a diagnosis in the UK for the condition can expect to wait up to a year for an answer following several assessment sessions with a clinician. ADHD Foundation will continue to use QbTest and support schools utlising QbCheck in order to reduce delays to diagnosis.
Also launched at the conference is the Braingaze objective ADHD test. ADHD Foundation will be the first in the UK to pilot Braingaze from this month with families with a history of ADHD and autism.
Speaking at the conference, Dr Tony Lloyd, ADHD Foundation CEO, said:
“We have worked with Qbtech for four years, and we were among the first in the UK to use its groundbreaking QbTest technology which is now commonplace in the NHS and has reduced costs and time to diagnosis significantly. QbCheck is an exciting new development as it will help SENCOs and school professionals provide high quality, evidence-based referrals.”
Qbtech believe that ADHD care can be transformed through the provision of objective data to professionals in health and education. Qbtech are market leaders in ADHD testing, and work across 11 countries with thousands of clinicians and are currently running more than 30 clinical trials into ADHD and associated conditions.
Tony Doyle, managing director, Qbtech Ltd, said:
“SENCOs and teachers play a vital role in referring children who may have ADHD, QbCheck helps them to do so with greater confidence. Most people respond really well to treatment but first they must be assessed by a clinican. With QbCheck you can begin to change the life of a child with ADHD, all you need is 15 minutes and a laptop.”
Braingaze uses eye-tracking technology to capture eye vergence and artificial intelligence algorithms to classify patients ADHD vs non-ADHD. Braingaze has in Spain clinically validated its ability to provide instant diagnosis assessment for children as young as seven-years-old, and if this ability is re-confirmed in the UK pilot, this could save the NHS money further down the line. While not a replacement to the psychological assessment currently in place, Braingaze could be a useful tool in the evaluation process.
Hans Supèr, Braingaze co-founder, believes eye-tracking technology can more objectively define if a child has ADHD, with scientific evidence to support its case. The company continues to conduct trials into identifying ADHD in adolescents and adults, as well as other cognitive impairments such as autism and dyslexia.
Hans Supèr, professor at the University of Barcelona, said:
“The Braingaze test is accessible, quick and affordable, but more importantly, is a practical tool that provides objectivity for psychiatrists for diagnosis. We look forward to bringing it to the UK for the first time and working in partnership with ADHD Foundation, furthering their incredible work in supporting children, young people and their families living with ADHD.”
Qbtech and Braingaze have joined other internationally renowned experts in the field of mental health,autism and ADHD in Liverpool this week for the ADHD Foundation annual conference (October 13 and 14, 2016).
The largest event of its kind in Europe, this year’s conference welcomes over 800 delegates from Italy, France, Sweden, Ireland, Spain and the UK - the biggest attendance in its four-year history. Taking place across two days, the conference explores new ideas, approaches and best practice in health, social care and education for children, young people and adults with ADHD and Autism Spectrum Disorder (ASD), and other neuro developmental conditions.
ADHD Foundation works to promote and improve the mental health outcomes, educational attainment, employability, social inclusion and life chances of children, young people and adults affected by ADHD through early intervention with a range of training and therapies.
For more information about ADHD Foundation, visit www.adhdfoundation.org.uk or call 0151 237 2661.